Clinical Trial Update: A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects [Phase 2]

View source ↗

Summary

A Phase 2 study assessing safety and immunogenicity of one and two doses of IMVAMUNE smallpox vaccine in vaccinia-experienced adults aged 56-80 years; status co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• IMVAMUNE (Modified Vaccinia Ankara (MVA))

Snippet

Sponsor: Bavarian Nordic | Conditions: Smallpox | Phase 2 | Status: COMPLETED | Results posted: 2019-01-10